Glaxosmithkline Plc Adr Stock Today
| GSK Stock | USD 33.70 0.35 1.05% |
Performance0 of 100
| Odds Of DistressLess than 20
|
GlaxoSmithKline PLC is selling for 33.70 as of the 21st of November 2024. This is a 1.05% increase since the beginning of the trading day. The stock's last reported lowest price was 33.17. GlaxoSmithKline PLC has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Note, on November 16, 2023, Senator Tommy Tuberville of US Senate acquired under $15k worth of GlaxoSmithKline PLC ADR's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of July 1986 | Category Healthcare | Classification Health Care |
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. The company has 2.04 B outstanding shares of which 16.29 M shares are currently shorted by investors with about 3.29 days to cover. More on GlaxoSmithKline PLC ADR
Moving together with GlaxoSmithKline Stock
Moving against GlaxoSmithKline Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
GlaxoSmithKline Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Emma Walmsley | ||||
| Thematic Idea | Healthcare (View all Themes) | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Pharmaceutical, Healthcare, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsGlaxoSmithKline PLC can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand GlaxoSmithKline PLC's financial leverage. It provides some insight into what part of GlaxoSmithKline PLC's total assets is financed by creditors.
| |||||
GlaxoSmithKline PLC ADR (GSK) is traded on New York Stock Exchange in USA. It is located in 980 Great West Road, Brentford, United Kingdom, TW8 9GS and employs 70,212 people. GlaxoSmithKline PLC is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a total capitalization of 68.04 B. GlaxoSmithKline PLC ADR runs under Pharmaceuticals sector within Health Care industry. The entity has 2.04 B outstanding shares of which 16.29 M shares are currently shorted by investors with about 3.29 days to cover.
GlaxoSmithKline PLC ADR has about 3.72 B in cash with 6.77 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32.
Check GlaxoSmithKline PLC Probability Of Bankruptcy
Ownership AllocationGlaxoSmithKline PLC ADR has a total of 2.04 Billion outstanding shares. Roughly 84.57 (percent) of GlaxoSmithKline PLC outstanding shares are held by general public with 0.056 % owned by insiders and only 15.38 pct. by outside corporations. Please note that on November 16, 2023, Senator Tommy Tuberville of US Senate acquired under $15k worth of GlaxoSmithKline PLC ADR's common stock.
Check GlaxoSmithKline Ownership Details
GlaxoSmithKline Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2024-06-30 | 4.2 M | |
| Eversept Partners, Llc | 2024-09-30 | 4.1 M | |
| Provident Trust Company | 2024-09-30 | 4 M | |
| Grantham, Mayo, Van Otterloo & Co., Llc | 2024-09-30 | 3.7 M | |
| Hsbc Holdings Plc | 2024-06-30 | 3.6 M | |
| Equity Investment Corp | 2024-09-30 | 3.5 M | |
| Lmr Partners Llp | 2024-06-30 | 3.3 M | |
| Camber Capital Management Llc | 2024-09-30 | 3 M | |
| Hotchkis & Wiley Capital Management Llc | 2024-06-30 | 2.7 M | |
| Dodge & Cox | 2024-09-30 | 68.1 M | |
| Fmr Inc | 2024-09-30 | 29 M |
GlaxoSmithKline PLC Historical Income Statement
GlaxoSmithKline Stock Against Markets
GlaxoSmithKline PLC Corporate Directors
| Lynn Elsenhans | Independent Non-Executive Director | Profile | |
| Harry Dietz | Non-Executive Independent Director, Scientific and Medical Expert | Profile | |
| Charles Bancroft | Non-Executive Independent Director | Profile | |
| Vivienne Cox | Independent Non-Executive Director and Workforce Engagement Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.28) | Dividend Share 0.61 | Earnings Share 1.54 | Revenue Per Share 15.38 | Quarterly Revenue Growth (0.02) |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.